Skip to main content
. Author manuscript; available in PMC: 2022 May 15.
Published in final edited form as: Bioorg Med Chem Lett. 2021 Mar 17;40:127965. doi: 10.1016/j.bmcl.2021.127965

Table 1:

Concentration producing 50% growth inhibition (IC50, μM±SEM) of the carboxylic acid derivatives 3a-d on HepG2 and Hep3B liver cancer cells

Cpd R Antiproliferative activity, μM FAK inhibitory
activity, nM
HepG2 Hep3B
3a Methyl 8.83±0.52 3.87±0.23 N.T.
3b Ethyl 40.97±2.4 17.94±1.05 N.T.
3c Allyl 4.72±0.28 2.88±0.17 36.37±1.8
3d Phenyl 3.78±0.22 4.83±0.28 18.10±0.92
Doxorubicin - 1.99±0.12 7.21±0.42 N.T.
GSK2256098 - 3.24±0.57 6.91±1.02 22.14±1.12